• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » U.S. Tops List of Trial Startups With China Making Progress in Phase 1

U.S. Tops List of Trial Startups With China Making Progress in Phase 1

China on Global
December 8, 2019
Colin Stoecker

China is rapidly making headway in phase 1 clinical trials, although the U.S. remains the world leader in phase 1 through 3 trials overall.

The U.S. had 614 phase 1 trial starts, followed by 194 in China and 147 in the UK, according to 2017 data reviewed by the Association of the British Pharmaceutical Industry (ABPI).

China, however, is still struggling in later phase startups. China scored ninth place for phase 2 startups with only 122 new trials, and 11th place in phase 3 trials with 146. The report attributes the low ranking in late-phase Chinese trials to a lack of trained trial managers and an inefficient regulatory environment.

The U.S. had the most phase 2 trial startups at 970 in 2017, the report says. The UK did start the most phase 2 trials in Europe that year, but it was well below the U.S. at 253. Germany was a close third behind the UK for phase 2 starts with 232 begun.

Although the UK might be a leader in Europe for early phase research, other countries like Germany, Spain, the U.S. and Canada all started more phase three trials in 2017. The U.S. led the pack with 528 trials. The UK lagged behind Germany and Spain in phase 3 trials.

New to the rankings are Brazil, Switzerland and South Africa. They were at the bottom of the list in phase 3 trial starts with Brazil, 116; South Africa, 72; and Switzerland at 65.

China is also making headway in therapeutic areas ranked in the report. China started the second highest number of oncology trials across all phases with 236 in 2017, behind the U.S. at a dominant 866. The previous year, China started 192 cancer drug trials.

Spain was close behind China in 2017 with 226 cancer trials initiated, then France with 216, followed by the UK and Japan, both with 210.

For cardiovascular disease drug research, the U.S. led in 2017 with 222 trials initiated. The next two highest were Japan with 103, and Germany with 100 trials started.

For nervous system disease drug trials started, the U.S. was again the leader with 215 trials, followed by Germany with 66, and the UK with 61.

For immune disorders, the U.S. started 162 trials in 2017, followed by Germany with 97, and Canada with 80.

To combat the new rise in antimicrobial resistance in recent years, the U.S. started 139 trials for infectious diseases, followed by the UK with 48, and Spain with 40.

Read the report here: https://bit.ly/2OTcWZn.

Number of Commercial Clinical Trials Started in 2017, by Phase and Country

Rank

Country

Phase I

Country

Phase II

Country

Phase III

1

USA

614

USA

970

USA

528

2

China

194

UK

253

Germany

276

3

UK

147

Germany

232

Canada

259

4

Germany

136

Japan

227

Spain

258

5

Japan

111

Spain

204

UK

243

6

Australia

82

France

176

Poland

243

7

Canada

72

Canada

176

Italy

235

8

France

52

Italy

141

Japan

235

9

Spain

49

China

122

France

210

10

Italy

19

Australia

112

Australia

180

11

Poland

15

Poland

98

China

146

12

Switzerland

14

Switzerland

30

Brazil

116

13

Brazil

10

Brazil

23

South Africa

72

14

South Africa

5

South Africa

17

Switzerland

65

Source: Association of British Pharmaceutical Industry

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing